Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients
NCT01684397Phase 2Active, not recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Nov 2012
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib, bevacizumab in clear cell renal cell carcinoma (ccRCC), sponsored by Roswell Park Comprehensive Cancer Center. Started Nov 2012; status: active, not recruiting.
02
Drugs
pazopanibbevacizumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01684397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01684397.